ERBB2 and breast carcinoma: These results suggested the p-RPS6 level as a predictive marker for the susceptibility of HER2+ breast cancers to anti-HER2 drugs and a feasibility marker of drugs for a combination strategy for the trastuzumab-resistant HER2+ breast cancers [360].